Eykona has closed two significant six-figure investments with a well-known and highly credible VC. Thiese are being used to accelerate key technical developments and speed commercial growth. The company is now pursuing a full Series A investment round which will be deployed to bring the technology to fruition and achieve regulatory clearances and first sales. In addition the clinical, sales and opserations teams will be recruited. The intention is to raise a Series B round based upon positive news flow to take the company through to profitability early in year 3. Eykona anticipates growing significant shareholder value prior to the second round by performing the following key milestones: